000K  utf8
1100  2020$c2020-04
1500  eng
2050  urn:nbn:de:gbv:27-dbt-20230515-203500-002
2051  10.1038/s41375-020-0776-2
3000  Hochhaus, A.
3010  Apperley, J. F.
3010  Baccarani, M.
3010  Cervantes, F.
3010  Clark, R. E.
3010  Cortes, J. E.
3010  Deininger, M. W.
3010  Guilhot, F.
3010  Hehlmann, R.
3010  Hjorth-Hansen, H.
3010  Hughes, T. P.
3010  Janssen, J. J. W. M.
3010  Kantarjian, H. M.
3010  Kim, D. W.
3010  Larson, R. A.
3010  Lipton, J. H.
3010  Mahon, F. X.
3010  Mayer, J.
3010  Nicolini, F.
3010  Niederwieser, D.
3010  Pane, F.
3010  Radich, J. P.
3010  Rea, D.
3010  Richter, J.
3010  Rosti, G.
3010  Rousselot, P.
3010  Saglio, G.
3010  Saußele, S.
3010  Schiffer, C.
3010  Silver, R. T.
3010  Soverini, S.
3010  Steegmann, J. L.
3010  Turkina, A.
3010  Zaritskey, A.
4000  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia  [Hochhaus, A.]
4060  19 Seiten
4209  The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
4950  https://doi.org/10.1038/s41375-020-0776-2$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:27-dbt-20230515-203500-002$xR$3Volltext$534
4961  https://www.db-thueringen.de/receive/dbt_mods_00057304
5051  610
5550  Chronic myeloid leukaemia
5550  Targeted therapies